Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley Acquires 50,000 Shares of Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average cost of C$2.77 per share, with a total value of C$138,490.00.

Cardiol Therapeutics Stock Performance

Shares of CRDL opened at C$2.70 on Tuesday. The firm has a 50-day moving average of C$2.99 and a 200-day moving average of C$2.20. Cardiol Therapeutics Inc. has a one year low of C$0.91 and a one year high of C$4.26. The company has a market cap of C$186.30 million, a PE ratio of -5.74 and a beta of 0.68. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.81 and a quick ratio of 6.84.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Cardiol Therapeutics in a research report on Monday, April 22nd.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.